SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on February 13, 2023, covering events occurring on February 8, 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing discloses the entry into a material definitive agreement involving the sale of unregistered equity securities.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Total Consideration Raised: $409,994.75
- Common Stock Sold: 382,308 shares at $1.07242 per share
- Warrants Issued: Warrants to purchase up to 191,154 shares
- Warrant Exercise Price: $1.00992 per share
- Warrant Terms: Exercisable six months after issuance; expire five and one-half years after issuance
The filing text does not provide clear values for the company's overall revenue, profit, cash flow, operating margins, total debt, or liquidity position as of the reporting date.
Material Changes and Unusual Items
The primary material change is the increase in outstanding common stock and the creation of potential future dilution through the issuance of warrants. The securities were sold to accredited investors in reliance on exemptions under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933. No other material changes to operations or financial condition are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard representations and warranties typical for such transactions. The transaction was executed to raise capital, though the specific use of proceeds is not detailed in the provided text.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Confirm the use of proceeds from the $409,994.75 raised, as it is not explicitly stated in the summary.
- Monitor the warrant exercise schedule beginning six months post-issuance for potential future share issuance.
- Check subsequent filings for updated liquidity and cash position following this capital raise.